Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978786721> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W1978786721 endingPage "1014" @default.
- W1978786721 startingPage "1008" @default.
- W1978786721 abstract "The objective of this study was to describe the potential metabolism and protein-binding interactions with karenitecin, a novel computer-engineered, highly lipophilic camptothecin. Individual cloned cytochrome P450 (CYP450) isoenzymes were used to determine, in vitro, the metabolism of karenitecin. Known substrates and inhibitors of each isoenzyme were employed to evaluate CYP450 drug interactions with karenitecin. To assess the extent, variability, and role of various drug-binding proteins, the authors examined, in vitro, the effects of both albumin (Alb) and alpha-acidic glycoprotein (AAG) on karenitecin plasma protein binding (PPB). Equilibrium dialysis techniques were used to measure the free fraction of karenitecin in the presence of varying ratios of Alb and AAG. Artificial plasma, spiked with karenitecin, was dialyzed for 72 hours at 37 degrees C against a Sorensen's buffer solution using regenerated cellulose membranes having a molecular weight cutoff of 12 to 14 kDa. Additional protein-binding experiments were conducted to assess the potential PPB drug interactions between karentiecin and other highly protein-bound drugs commonly used in the treatment of cancer patients. In vitro experiments suggested that karenitecin is metabolized by CYP450 3A4, 2C8, and 2D6 isoenzymes and is an inhibitor of the CYP450 3A4 and 2C8 isoenzymes. The mean (+/- SD) percentage of karenitecin bound to plasma proteins was 99.1% +/- 0.27%. The extent of karenitecin protein binding was directly proportional to the plasma concentration of AAG. Protein-binding displacement interactions were observed in the in vitro experiments with phenobarbital, phenytoin, mitoxantrone, and salicylic acid. It was concluded that karenitecin has the potential to alter CYP450 3A4 and 2C8 drug-metabolizing activity. In addition, in vitro PPB evaluations have demonstrated that karenitecin may displace other highly PPB drugs and that slight variations in plasma AAG concentration may result in large variations in free drug exposure. Each of these interactions could potentially result in increasing the toxicity or alter the efficacy of combination anticancer drug therapy if they are significant in patients. Future karenitecin clinical trials should include studies to monitor or evaluate the effects of these potential drug interactions on the overall toxicity of karenitecin when used in combination with other drugs." @default.
- W1978786721 created "2016-06-24" @default.
- W1978786721 creator A5052309533 @default.
- W1978786721 creator A5077278547 @default.
- W1978786721 creator A5083929738 @default.
- W1978786721 creator A5086839893 @default.
- W1978786721 date "2003-09-01" @default.
- W1978786721 modified "2023-10-17" @default.
- W1978786721 title "Evaluation of In Vitro Drug Interactions with Karenitecin, a Novel, Highly Lipophilic Camptothecin Derivative in Phase II Clinical Development" @default.
- W1978786721 cites W1835830368 @default.
- W1978786721 cites W1952371628 @default.
- W1978786721 cites W1971847818 @default.
- W1978786721 cites W1975616471 @default.
- W1978786721 cites W2027333133 @default.
- W1978786721 cites W2038337883 @default.
- W1978786721 cites W2043703023 @default.
- W1978786721 cites W2085054765 @default.
- W1978786721 cites W2085932819 @default.
- W1978786721 cites W2107015590 @default.
- W1978786721 cites W2267283804 @default.
- W1978786721 doi "https://doi.org/10.1177/0091270003255921" @default.
- W1978786721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12971034" @default.
- W1978786721 hasPublicationYear "2003" @default.
- W1978786721 type Work @default.
- W1978786721 sameAs 1978786721 @default.
- W1978786721 citedByCount "9" @default.
- W1978786721 countsByYear W19787867212013 @default.
- W1978786721 countsByYear W19787867212015 @default.
- W1978786721 countsByYear W19787867212017 @default.
- W1978786721 crossrefType "journal-article" @default.
- W1978786721 hasAuthorship W1978786721A5052309533 @default.
- W1978786721 hasAuthorship W1978786721A5077278547 @default.
- W1978786721 hasAuthorship W1978786721A5083929738 @default.
- W1978786721 hasAuthorship W1978786721A5086839893 @default.
- W1978786721 hasConcept C108625454 @default.
- W1978786721 hasConcept C126322002 @default.
- W1978786721 hasConcept C146543888 @default.
- W1978786721 hasConcept C185592680 @default.
- W1978786721 hasConcept C202751555 @default.
- W1978786721 hasConcept C2776054734 @default.
- W1978786721 hasConcept C2776125364 @default.
- W1978786721 hasConcept C2779306644 @default.
- W1978786721 hasConcept C2779682216 @default.
- W1978786721 hasConcept C2780035454 @default.
- W1978786721 hasConcept C2781233306 @default.
- W1978786721 hasConcept C30787643 @default.
- W1978786721 hasConcept C51639874 @default.
- W1978786721 hasConcept C55493867 @default.
- W1978786721 hasConcept C62231903 @default.
- W1978786721 hasConcept C71924100 @default.
- W1978786721 hasConcept C86803240 @default.
- W1978786721 hasConcept C89311334 @default.
- W1978786721 hasConcept C98274493 @default.
- W1978786721 hasConceptScore W1978786721C108625454 @default.
- W1978786721 hasConceptScore W1978786721C126322002 @default.
- W1978786721 hasConceptScore W1978786721C146543888 @default.
- W1978786721 hasConceptScore W1978786721C185592680 @default.
- W1978786721 hasConceptScore W1978786721C202751555 @default.
- W1978786721 hasConceptScore W1978786721C2776054734 @default.
- W1978786721 hasConceptScore W1978786721C2776125364 @default.
- W1978786721 hasConceptScore W1978786721C2779306644 @default.
- W1978786721 hasConceptScore W1978786721C2779682216 @default.
- W1978786721 hasConceptScore W1978786721C2780035454 @default.
- W1978786721 hasConceptScore W1978786721C2781233306 @default.
- W1978786721 hasConceptScore W1978786721C30787643 @default.
- W1978786721 hasConceptScore W1978786721C51639874 @default.
- W1978786721 hasConceptScore W1978786721C55493867 @default.
- W1978786721 hasConceptScore W1978786721C62231903 @default.
- W1978786721 hasConceptScore W1978786721C71924100 @default.
- W1978786721 hasConceptScore W1978786721C86803240 @default.
- W1978786721 hasConceptScore W1978786721C89311334 @default.
- W1978786721 hasConceptScore W1978786721C98274493 @default.
- W1978786721 hasIssue "9" @default.
- W1978786721 hasLocation W19787867211 @default.
- W1978786721 hasLocation W19787867212 @default.
- W1978786721 hasOpenAccess W1978786721 @default.
- W1978786721 hasPrimaryLocation W19787867211 @default.
- W1978786721 hasRelatedWork W2011541218 @default.
- W1978786721 hasRelatedWork W2018793618 @default.
- W1978786721 hasRelatedWork W2038771264 @default.
- W1978786721 hasRelatedWork W2048010235 @default.
- W1978786721 hasRelatedWork W2048062735 @default.
- W1978786721 hasRelatedWork W2058990479 @default.
- W1978786721 hasRelatedWork W2066600107 @default.
- W1978786721 hasRelatedWork W2101087257 @default.
- W1978786721 hasRelatedWork W2315847782 @default.
- W1978786721 hasRelatedWork W811018183 @default.
- W1978786721 hasVolume "43" @default.
- W1978786721 isParatext "false" @default.
- W1978786721 isRetracted "false" @default.
- W1978786721 magId "1978786721" @default.
- W1978786721 workType "article" @default.